I have made it my mission to discover and develop drugs that will prevent and cure Alzheimer’s disease within the next ten years.

Over 36 million people worldwide suffer from Alzheimer’s disease and related dementias, without hope of survival. It is critical that we continue to pursue the most promising research to find effective treatments and halt this devastating disease.

Please join us in the quest to cure Alzheimer’s disease with the knowledge that 100% of any donation you make will go directly towards research.

There is hope in drug discovery.
**Mission**

The mission of the Alzheimer’s Drug Discovery Foundation (ADDF) is to accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s disease, related dementias and cognitive aging.

**Impact**

The ADDF has granted more than $51 million to fund nearly 400 Alzheimer's drug discovery programs and clinical trials in academic centers and biotechnology companies in 18 countries.

**Approach**

Founded in 1998 by Co-Chairmen Leonard A. and Ronald S. Lauder, the ADDF provides critical seed funding to leading scientists conducting breakthrough drug discovery and early clinical research.

The ADDF does not commit financial support to any single scientific approach or institution. Its strategy is to increase the chance of finding a cure for Alzheimer’s disease by supporting the most promising, diverse and novel research projects anywhere in the world, as well as to develop a portfolio of drugs in the pipeline and a network of effective partnerships.

*All of the ADDF’s administrative and overhead costs are covered by a private foundation enabling 100% of all funds raised to go directly to Alzheimer’s drug research and related programs.*

Many of the ADDF's grants are structured as investments, providing a return that is reinvested in new drug research.
For the ADDF, 2011 has been a year of promising strides in scientific research, expansion of innovative programs, and collaborative support from the Alzheimer’s community.

Working with our Scientific Review Board, we reviewed over 300 new proposals and provided funding for a record 41 research programs that address key drug targets, totaling over $5.5 million and supporting Alzheimer’s disease drug discovery around the globe.

In addition to the promise of these new investments, in 2011 we saw measurable impact with our previously funded programs, including:

- **Avid Radiopharmaceuticals:** The ADDF provided the critical seed funding for early research at the University of Pennsylvania that led to Avid’s development of a novel brain-imaging test for Alzheimer’s disease. This diagnostic technology is being evaluated by the U.S. Food and Drug Administration.

- **Allon Therapeutics:** Allon, co-founded by the ADDF, is developing a nasal spray that protects brain cells from damage. The spray is now in Phase 3 clinical trials for progressive supranuclear palsy, a neurodegenerative disease related to Alzheimer’s disease.

As evidence of the scientific success of these and several other ADDF-funded programs, we received returns totaling $400,000. Through our unique venture philanthropy model, we will reinvest those funds into new research.

In 2011, we also continued our focus on building public/private partnerships to leverage resources and expertise towards a common goal. For example, the Robert A. & Renée E. Belfer Family Foundation issued a $1 million challenge grant and established the ADDF/Belfer ApoE Therapeutics Innovation Program. The ADDF met the Belfers’ challenge by securing additional $1 million pledges from The Charles Evans Foundation, an anonymous American donor and an anonymous Canadian donor. With the Canadian gift, which will be used to fund clinical trials in Canada, the ADDF began the process of registering its first non-U.S. based affiliate, the ADDF of Canada.

Additionally, the ADDF connected investigators from around the world through scientific conferences and raised awareness about Alzheimer’s disease and the importance of drug discovery through signature special events.

Our approach supports talented scientists who are taking brave and risky steps to develop drugs for this devastating disease. Thanks to your generous and continued support, we are able to rapidly accelerate movement towards a cure.

Howard Fillit, MD

Nancy Lynn

Executive Director

Executive Vice President
The ADDF has funded nearly 400 drug programs.
### Select ADDF-Funded Drugs in the Pipeline

The ADDF has funded nearly 400 Alzheimer’s drug discovery programs and clinical trials in academic centers and at biotechnology companies worldwide. Below, we highlight select programs, grouped by therapeutic category.

<table>
<thead>
<tr>
<th>Therapeutic Target</th>
<th>Preclinical</th>
<th>Clinical</th>
<th>FDA Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Screening/Chemistry</td>
<td>Animal Studies</td>
<td>IND-Enabling</td>
</tr>
<tr>
<td><strong>AMYLOID</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prana Biotechnology*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zapaq, Inc./Comentis*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mayo Clinic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tel Aviv University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cognition Therapeutics*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amicus Therapeutics*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TAU</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allon Therapeutics*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simon Fraser University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Signum Biosciences*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Max-Planck Institute</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New York University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yuma Therapeutics*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NEUROPROTECTION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>University of South Florida</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emory University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>University of California, San Diego</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virginia Commonwealth</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmatrophix*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varinel*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>University of California, Irvine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Northwestern University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boston University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AgeneBio*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>APOE AND VASCULAR</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duke University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weill Cornell</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gladstone Institute</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rockefeller University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Madera*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>University of British Columbia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ENERGY UTILIZATION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolic Solutions*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Columbia University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EARLY DETECTION AND DIAGNOSIS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>University of Pennsylvania</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ohio State University</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Biotechnology Companies
Many scientists believe that multiple factors may contribute to or trigger Alzheimer’s disease. The following is a list of six that the ADDF has targeted.

**AMYLOID** | “Amyloid plaques” are clumps of abnormal proteins that accumulate in the brain of an Alzheimer’s patient and disrupt mental function. Amyloid is the leading drug target of many pharmaceutical companies, which are investing billions of dollars in potential treatments with the aim to remove amyloid from the brains of living patients. We will soon discover if this strategy works — in 2012 or 2013 several anti-amyloid drugs will be tested in late-stage clinical trials.

**TAU** | Tau is a protein in Alzheimer’s disease that accumulates into “tangles” within nerve cells in the brain causing massive dysfunction and ultimately cell death. These tangles are a hallmark of Alzheimer’s disease as well as other related disorders. Since these tangles are so closely associated with nerve cell death, restoring the normal condition of tau protein is an important target for new drug development.

**ENERGY UTILIZATION/MITOCHONDRIA** | All cells need energy to maintain healthy function, and the brain is a high “energy user.” As we age, our brain cells use energy less efficiently. Decreased energy utilization is one of the earliest characteristics seen in the brains of Alzheimer’s patients. To counteract this loss, scientists are working to develop drugs that could enhance the function of the mitochondria, the energy powerhouse of the cell.

**APOE** | ApoE (apolipoproteinE) is the most significant genetic risk factor for late-onset Alzheimer’s disease. A certain type of ApoE (ApoE E4) increases a person’s risk of developing Alzheimer’s before 75 by up to 20-fold. ADDF-funded scientists are investigating several strategies for developing drugs to modify this genetic risk.

**VASCULAR SYSTEM** | Damage to the body’s blood vessel network or “vasculature” can starve the brain of oxygen and vital nutrients needed for cells to work properly. Nerve cells are particularly vulnerable. Therefore, drug development strategies that increase blood flow or promote a healthy vascular system may prevent the nerve cell dysfunction that is seen in Alzheimer’s disease.

**NEUROPROTECTION** | Neurodegenerative diseases such as Alzheimer’s are characterized by nerve cell death. Treatment strategies to guard nerve cells and keep them from dying are referred to as “neuroprotection.”
Where We Fund

The ADDF supports the most promising and diverse research projects around the world.
## Select Current Programs

### Preclinical Drug Discovery

The ADDF’s preclinical program funds research focused on translating the knowledge we have gained about the underlying causes of Alzheimer’s disease into drugs. In 2011, 60% of our funding went towards preclinical drug discovery.

**Michela Stucchi, PhD**  
Axxam sPA  
Milan, Italy

Dr. Stucchi and team at Axxam are developing chemical compounds that block the pro-inflammatory signals in the brain that exacerbate disease progression by inhibiting the molecular target, “P2X7 receptor.” These molecules will lay the ground for further development toward oral, selective drugs useful for treatment of Alzheimer’s disease as well as other neurodegenerative disorders.

> “...the start-up of an innovative idea and the rapid progression to a product ready for development would not have been possible without ADDF funding.”

**D. Martin Watterson, PhD**  
Northwestern University  
Evanston, Illinois

Dr. Watterson is developing a novel chemical that inhibits a protein called “p38MAPK.” p38MAPK is involved in mediating the effects of inflammation and triggering progression of brain disorders such as Alzheimer’s disease. His novel chemical p38MAPK inhibitor is now being optimized for safety and efficacy.

### Program to Accelerate Clinical Trials (PACT)

The ADDF’s PACT supports early phase pilot clinical trials that test new potential drugs for Alzheimer’s disease. In 2011, 19% of our funding went towards clinical studies.

**Dianne Angus**  
Prana Biotechnology, Ltd.  
Melbourne, Australia

Prana’s clinical trial is employing brain imaging to monitor the effects of its novel drug PBT2 on amyloid deposition. PBT2 has been shown to decrease accumulation of beta-amyloid in the brain and generally protect brain cells from degeneration. Enrollment of the first patients in this trial is expected to begin in early 2012.

> “The ADDF has stepped in to support us at a very significant time. Success in this trial will position PBT2 as a potential drug to treat an underlying cause of Alzheimer’s.”

**James Bennett, MD, PhD**  
Virginia Commonwealth University  
Richmond, Virginia

Dr. Bennett and his team are currently treating patients in the early stage of Alzheimer’s disease with a novel neuroprotective drug, the chemical R(+)Pramipexole (R(+)PPX). R(+)PPX could protect the brain against damage cause by oxidative stress and has been shown to slow disease progression in Alzheimer’s patients. Enrollment is underway and expected to be completed in 2012.

> “The ADDF has filled a critical role by supplying funding during the period between initial drug discovery and early clinical studies, when there is typically very little money for support.”

*The funding from the ADDF represents important and essential financial support for this relevant discovery program.*
In 2011, the ADDF established the ADDF/Belfer ApoE Therapeutics Innovation Program to accelerate the development of novel therapeutics specifically designed to target ApoE pathological mechanisms. In 2011, four research projects were funded through this program, totaling $512,500.

**Jerry Colca, PhD**
Metabolic Solutions
Development Company
Kalamazoo, Michigan

Dr. Colca and his team are testing MSDC-0160, a compound for the treatment of diabetes, for efficacy in early-stage Alzheimer’s patients. ADDF-funded preclinical studies showed that MSDC-0160 reduced amyloid plaques in the brain — a key hallmark of Alzheimer’s disease — and that the drug improved learning.

“... had it not been for funding by the ADDF, we would not have been able to persuade our investors that we should also look at Alzheimer’s disease.”

**Steve Paul, MD**
Weill Medical College of Cornell University
New York, New York

Dr. Paul’s research aims to use modern gene delivery technology to insert the ApoE E2 gene, known to protect against the development of Alzheimer’s disease, into the brain of both mice and monkeys in anticipation of a possible human clinical trial to treat or prevent Alzheimer’s disease.

“While clearly a risky project, the potential rewards (for Alzheimer’s disease patients) are significant ... this is just the kind of research that ADDF often supports and which may eventually prove instrumental in coming up with effective disease-modifying therapies for this horrific disease.”

**Cheryl Wellington, PhD**
University of British Columbia Hospital
British Columbia, Canada

Dr. Wellington’s research has shown that the amount of cholesterol carried on ApoE determines how much Abeta (a pathological hallmark of Alzheimer’s disease) is deposited in the brain. Her team also discovered that ApoE receives fats from the cholesterol transporter ABCA1 and that increasing ABCA1 function facilitates Abeta removal and restores memory. Dr. Wellington’s objective is to identify new molecules that safely increase ApoE and/or ABCA1 expression — such compounds may effectively prevent or treat Alzheimer’s disease.

“Working with the ADDF feels like a partnership, which I find very motivating.”

**Charles River Laboratories International, Inc.**
The ADDF partnered with Charles River to fund studies exploring novel treatments in aged rats. The model mimics features of human aging, the single most significant risk factor in Alzheimer’s disease.

**The Association for Frontotemporal Degeneration (AFTD)**
The ADDF renewed its collaboration with the AFTD to fund research that may identify indicators or “biomarkers” of frontotemporal dementia, a critical first step towards discovering treatments for the devastating disease.
Conferences  Our 2011 scientific conferences promoted the exchange of ideas, the sharing of research results, and the formation of strategic alliances to further drug development goals.

5th Drug Discovery for Neurodegeneration Conference: An Intensive Course on Translating Research into Drugs
San Diego, CA
February 6-8, 2011
The ADDF’s annual conference, planned in conjunction with the National Institutes of Health, attracted approximately 140 academic, industry and government scientists from around the world and trained scientists on the process of drug discovery.

12th International Conference on Alzheimer’s Drug Discovery
Jersey City, NJ
September 26-27, 2011
This global conference, designed to accelerate the development of innovative treatments, attracted approximately 140 key stakeholders from the pharmaceutical, biotechnology, government and academic communities. Over 20 ADDF-funded scientists presented updates on their research progress.

Collaborative Conferences
The ADDF also hosted the four following conferences in collaboration with other scientific institutions:

- 6th International Pharmacoeconomic Conference on Alzheimer’s Disease
  February 3-4, 2011
  London, UK

- 10th International Congress on Alzheimer’s and Parkinson’s Diseases (“Drug Discovery for Alzheimer’s Disease” session)
  March 9-13, 2011
  Barcelona, Spain

- Targeting Synaptic Dysfunction in Alzheimer’s Disease
  (New York Academy of Sciences)
  May 18, 2011
  New York, NY

- Alzheimer’s Disease Venture Capital Roundtable
  (Orbimed Healthcare Fund Management)
  July 7, 2011
  New York, NY
To raise awareness and support, the ADFD hosted a series of informational meetings and receptions throughout the country, including three special events. 100% of funds raised went directly towards Alzheimer’s drug discovery.

The Inaugural Great Ladies Luncheon and Fashion Show
April 26, 2011
The Ritz-Carlton
Washington, DC

Executive Chairs
Leonard A. Lauder
Elise and Marc Lefkowitz

In partnership with Saks Fifth Avenue, the ADFD’s inaugural Great Ladies Luncheon and Fashion Show was held in loving memory of Estelle Gelman. Hosted by Andrea Mitchell and Kathleen Matthews, the luncheon attracted nearly 400 guests and raised more than $250,000.

Fifth Annual Connoisseur’s Dinner: To Live is to Think
April 28, 2011
Sotheby’s New York
New York, NY

Co-Chairs
Leonard A. Lauder
Nancy Corzine

The ADFD’s fifth annual Connoisseur’s Dinner raised $1.3 million for Alzheimer’s drug discovery research. Nancy Corzine was awarded the inaugural Chairman’s Award and Sotheby’s chairman, Jamie Niven, conducted the annual “Fund A Scientist” auction, which raised $314,614.

Hope on the Horizon: New Drugs for Alzheimer’s Disease
September 21, 2011
Jumeirah Essex House
New York, NY

Executive Chairs
Leonard A. Lauder
Nancy and Mel Goodes
Lynn Forester de Rothschild

Honorary Chairs
Bonnie Pfeifer Evans
Alice Shure

The ADFD’s second annual Fall Luncheon and Symposium brought together 275 guests and raised over $640,000. Dr. Daniel Skovronsky of Avid Radiopharmaceuticals was presented with The Charles Evans Award for Excellence, Paula Zahn hosted an onstage interview with Nobel Prize recipient, Dr. Eric Kandel, and Mel Goodes delivered special remarks.
Support Alzheimer’s Research

Alzheimer’s is a progressive, fatal neurodegenerative disease and the most common cause of dementia. It affects one in three Americans over the age of 80 and yet, there are currently no drugs available that prevent or even slow the course of the disease.

By 2050, the number of Americans suffering from Alzheimer’s disease is expected to triple, and the rapidly increasing costs of Alzheimer’s care could bankrupt the U.S. Medicare system. In 2012 alone, Alzheimer’s is projected to cost the U.S. economy $200 billion. Financing for early-stage drug research for Alzheimer’s remains insufficient, and there has never been a greater need for the ADDF.

There is hope in drug discovery. With your help, we can and will understand, treat, prevent and conquer this disease.

Please give generously today at www.ALZDiscovery.org
2011 Donors

Over $1,000,000
Anonymous (2)
The Robert A. and Renée E. Belfer Family Foundation
The Charles Evans Foundation

$100,000 to $999,999
Aetna Foundation
The Association for Frontotemporal Degeneration
Charles River
Ms. Nancy Corzine
Mr. and Mrs. Steven Crown
Mr. and Mrs. Mel Goodes
Mr. and Mrs. Leonard A. Lauder
The Leonard and Evelyn Lauder Foundation
Mr. and Mrs. Marc Lefkowitz
Mr. and Mrs. Randal Sandler

$50,000 to $99,999
Mr. and Mrs. Raymond Dalio
Sir Evelyn and Lady Lynn Forester de Rothschild
The Estée Lauder Companies Inc.
National Institutes for Health
Dr. Nathan E. Saint-Amand
Staples

$25,000 to $49,999
Alzheimer's Foundation of America
Ms. Carol S. Boulanger
Mr. and Mrs. Louis Caceres
Condé Nast Publications
Ms. Beth Rudin DeWoody
Elan Corporation, plc.
Flexjet
Mr. William P. Lauder
Le Papillon Ltd./Watson C. Warriner, Jr.
Mr. Philip Lovett
Macy's and Bloomingdale's
Merck Research Laboratories
The David A. and Mildred H. Morse Charitable Trust
The Neiman Marcus Group
Pfizer Inc.
Mr. and Mrs. William C. Rudin
Mr. and Mrs. William Ruprecht
Sotheby's
Mrs. Joan Sutton Straus
Tommy Hilfiger Corporate Foundation
Mr. and Mrs. Buzz Zaino

$10,000 to $24,999
Anonymous (1)
Mr. and Mrs. James D. Abrams
Avid Radiopharmaceuticals, Inc.
Mr. and Mrs. Scott Black
Bloomberg
Mr. and Mrs. Charles Cangro
Mr. and Mrs. Arthur Carter
Mr. and Mrs. Warren Diamond
Mr. and Mrs. Mitchell Eichen
Ernst & Young, LLP
Mr. Paul Fribourg
Teaman and Grace Fuite Foundation
Mr. and Mrs. Albert Glickman
Mr. and Mrs. Henry Goldberg
Leslie and Roslyn Goldstein Foundation
Mr. and Mrs. David Goodes
INOAC Packaging Group, Inc.
Mr. and Mrs. Howard Kessler
Mr. and Mrs. Gary Lauder
Mrs. Bonnie Englebardt Lautenberg
Mr. and Mrs. Jorge Lazo
Mr. and Mrs. Laurence C. Leeds, Jr.
Mr. and Mrs. Samuel Lehrman
Lilly USA, LLC
Mr. and Mrs. Alan J. Maguire
Ms. Dina Merrill and Mr. Ted Hartley
Mr. and Mrs. William Miller
Ms. Connie Milstein
Mr. and Mrs. Marc S. Moller
Mr. Jiro Murase
Mr. and Mrs. Andrew M. Paul
Mr. Thomas Pheasant
Mrs. Cynthia Hazen Polsky and Mr. Leon B. Polsky
Mr. and Mrs. Robert Prince
Janice M. Rudbart Charitable Foundation
Mr. and Mrs. Richard E. Salomon
Mr. and Mrs. George W. Schiele
Mr. and Mrs. Warren L. Scherwin
Seabrook Foundation
Tishman Speyer Properties, LP
Barbara and Donald Tober Foundation
Mr. and Mrs. John H. van Merkensteijn, III
Mr. and Mrs. George Vrindenburg,
The Vrindenburg Foundation
Mrs. Jeannette Sarkisian Wagner and Dr. Paul A. Wagner
Mr. and Mrs. Michael Weisman
Mr. and Mrs. Keith Wellin
Ms. Linda Zambelli, U.S. Trust
Mr. and Mrs. Robert Zarnegin
Lois and Andrew Zaro Family Charitable Trust
Mr. and Mrs. Carl Zelinsky

$5,000 to $9,999
Alton Therapeutics Inc.
The David and Barbara Baldwin Foundation
Ms. Karen H. Bechtel
Mr. Howard B. Bernick
Mr. and Mrs. Daniel S. Bernstein
Biogen Idec
Mr. and Mrs. James Cohen
Mr. David Deckelbaum
Mr. John D. Demsey
Mr. Donny Deutsch
Mr. and Mrs. Todd Eagle
The Edgerley Family Foundation
Mr. and Mrs. Joel S. Ehrenkranz
Mr. and Mrs. Melvyn J. Estrin
Michael J. Fox Foundation for Parkinson's Research
Mr. and Mrs. Fabrizio Freda
Mr. Gary Fuhrman
Mr. Richard I. Furman
Mr. Larry Gagosian
Mrs. Alma Gildenhorn
Goldman Sachs & Co. Matching Gifts Program
Ms. Gilda Gourlay
Anne and Kenneth Griffin in memory of Ms. Genevieve Gratz
Mr. and Mrs. Geoffrey Gund
Mr. and Mrs. David Heller
Mr. and Mrs. Roger Hertog
Mr. and Mrs. Raymond Hill
Ms. Judy Jackson and Mr. Bruce Haims
Mr. and Mrs. Richard Jaffe
Mr. Christopher Johnson
Mrs. Karen Johnson
Mr. Mitchell Kaneff, Arkay Packaging
Mr. and Mrs. Michael Katzke
Kekst and Company Incorporated
Mr. and Mrs. Richard Kurtz
Ms. Alexandra Lebenthal and
Mr. Jeremy Diamond
Mr. and Mrs. Matthew Lefkowitz
Mr. and Mrs. Samuel H. Lindenbaum
Ms. Angela Marriott
Mr. and Mrs. Kelly Martin
The McGowan Family Foundation
Edward and Sandra Meyer Foundation
Ms. Jennifer Miller and Mr. Mark Ehret
Mr. and Mrs. James N. Mills
Mutual of Omaha
National Multiple Sclerosis Society
Mr. and Mrs. Donald E. Newhouse
Susan & Elihu Rose Foundation, Inc.
Mrs. Janet C. Ross
Ms. Sharon Sager and Mr. Loring Swasey,
UBS Private Wealth
Mr. and Mrs. Gerald Schaeffer
Mr. and Mrs. Mitchell Schrage
Mr. and Mrs. Steve Shapiro
Mr. and Mrs. Jonathan M. Tisch
Mr. and Mrs. Juan Torruella
Mr. and Mrs. Robert Zink

$1,000 to $4,999
Princess Yasmin Aga Kahn
Aisling Capital LLC
Ms. Tina Alster
Mr. and Mrs. Claude Amadeo
Mr. and Mrs. Steven Ames
Mr. and Mrs. Richard Aneres
Aprelica Inc.
Mr. and Mrs. Robert Aquilina
Ms. Rosalin Atzwanger
Mr. and Mrs. Joe Bachelder
Ms. Marion Bachrach and Family
Ms. Jamie Baldinger
The Alec Baldwin Foundation, Inc.
Mr. and Mrs. Martin Balsam
Ms. Cynthia W. Bardes
Ms. Laurie Barry
Mr. and Mrs. Philip J. Bazelides
Mr. Leonard J. Bencivenga
Mr. and Mrs. Simon Beriro
The Honorable and
Mrs. Stuart Bernstein
Beyond Batten Disease Foundation
Mr. Steve Blacher
Mr. and Mrs. Robert S. Blank
Mr. and Mrs. Bernard Bloom
Mr. Thomas R. Boehlke
Mr. and Mrs. Stanley Bogen
Mr. Patrick Bousquet-Chavanne
Ms. Evelyn Brandt
Mrs. Nancy Taylor Bubes
Ms. Frances Burka
Ms. Buffy Cafritz
Mr. and Mrs. Michael Carr
Mr. Steve A. Casella
Chastest Corporation
Ms. Lois Chiles and Mr. Richard Gilder
Mr. Michael T. Cohen
Mr. and Mrs. Jerome Cohen
Ms. Virginia Coleman
Mr. and Mrs. Charles Collat, Sr.
Colliers International
Mrs. Joyce Cowin
Mr. and Mrs. John Craig
Ms. Barbara Dalton
Ms. Marcia Diamond
Mr. Kevin Dieterich
Ms. Amy DiGesio and Mr. Paul Rakowski
Mr. and Mrs. Charles M. Diker
Mr. and Mrs. John R. Dillon
Mrs. Cherrie Doggett
Mr. and Mrs. Kenneth Duberstein
Eckert Seamans Cherin Mellott, LLC
Mr. Harry Edelson
Mr. Peter Eliel
Euromotorcars
Mr. Stuart M. Fain
Mr. and Mrs. Robin L. Farkas
Mr. and Mrs. Thomas Farnsworth, Jr.
Ms. Samia Farouki
Mr. and Mrs. David C. Farrell
Ms. Mary Farrell
Ms. Ginny Feldman
Mr. and Mrs. Niall M. Ferguson
Ms. Andrea Stern Ferris
Mr. and Mrs. Harry Fields
Ms. Arti V. Finn and Mr. Chris Grewe
Mrs. Anne Ford
Mrs. Harriet Foster
Mr. Jay W. Freedman
Ms. Marcia French
Mrs. Emily T. Frick
Fross, Zelnick, Lehrman & Zissu, PC
Mrs. Veronique Gabai-Pinsky and
Mr. Joel Pinsky
Ms. Maria Gagnier
Gannon Vitolo Contracting LLC
The Honorable Richard N. Gardner
Mrs. Robert P. Garrett
Genentech USA
Geoffrey Beene Foundation
Alzheimer's Initiative
Ms. Beth Glassman
Mr. and Mrs. Jim Gordon,
The Edgewater Funds
Ms. Sylvia Greenberg
Alexis Gregory Foundation
Mr. and Mrs. Phil Gross
Ms. Agnes Gund
Mr. and Mrs. Louis Hagopian
Mr. and Mrs. Edmund Hajim
Mr. Peter Hanson
Mr. James E. Hanson, II
Mr. Chris Harris
Mrs. Bobba Paul Hauserman
Mr. and Mrs. Lawrence Herbert
Ms. Marlene Hess and Mr. James D. Zirin
Mr. Robert Higdon
Ms. Beth A. Hollister
Dr. and Mrs. Clifford Hudis
Mr. and Mrs. Joel Hyatt
JRS Dryfoos Charitable Lead Trust
JSW Lifesciences GmbH
Mr. and Mrs. Harry P. Kamen
Mr. and Mrs. George Kaufman
Ms. Karyn A. Khoury
Mr. James D. Kiggen
Mr. and Mrs. Ronald Klein
Mr. and Mrs. Frederick A. Klingenstein
Ms. Diana Kogan
Mr. and Mrs. Kevah Konner
Mr. John Kossow
Ms. Hoda Kotb
The H. Frederick Krimendahl II
Foundation
Mr. and Mrs. Peter Krulwitch
Ms. Joan Krupskas and Mr. Ted Barbour
Ms. Elizabeth Szancer Kujawski and
Mr. Tom Zoufaly
Ms. Solange Landau
The Larini Family Foundation
Ms. Carol Launer
Mr. and Mrs. Brian C. Lawlor
Mr. Michael Lefenfeld
Mr. Kevin Leifer
Ms. Eileen LeMonda
Ms. Thelma Z. Lenkin
Mr. and Mrs. Steven Levy
Ms. Judith Little
The Litwin Foundation, Inc.
Mr. and Mrs. Daniel S. Loeb
The Thomas H. and Jarman F. Lowder Foundation
Ms. Elizabeth Lowe
Mr. and Mrs. John D. Lowenberg, Sr.
The Honorable and Mrs. Earle I. Mack
Dr. and Mrs. Robert Magoon
Mr. and Mrs. Vincent Mai
Mr. Mark Maltzman
Ms. Anne Marino
Mr. and Mrs. Morris Mark
Marlborough Gallery, Inc.
Ms. Donna Marriott
Mr. and Mrs. Bennett Marshall
Mrs. Jack C. Massey/Jack C. Massey Foundation
Mr. and Mrs. Jonathan P. May
Ms. Carlyn McCaffrey
The McCance Foundation Trust
Mr. Henry Meagher
Ms. Tracy Mezzalingua
Mr. and Mrs. Sam Michaels
Mr. and Mrs. David Mitchell
Ms. Judith Mogul and Mr. Daniel J. Kramer
Mr. and Mrs. Daniel Neidich
Neurophage Pharmaceuticals, Inc.
Newmark and Company Real Estate Inc.
Mr. and Mrs. William A. Nitze
Mr. Robert O’Haver
Orbimed Advisors
Ms. Nancy Ottati
Mr. Alex Papachristidis
Mr. and Mrs. Timothy Pasik
Mr. and Mrs. Richard S. Pearman
Ms. Connie Anne Phillips
Mr. and Mrs. Michael Pierce
Pillsbury Winthrop Shaw Pittman LLP
Mr. and Mrs. John Pomerantz
Ms. Phebe Farrow Port
Mr. and Mrs. Stephen W. Porter
Ms. Elizabeth Rad
Mr. and Mrs. William Rayner
Mr. Lewis Rice
Ms. Denise Rich
Ms. Judith Ripka and Mr. Ronald Berk
Mrs. Sheila J. Robbins
Mr. and Mrs. Steve Robert
Rockefeller and Company Inc.
Dr. and Mrs. Leon Root
Benjamin M. Rosen Family Foundation
Mr. Joseph B. Rosenblatt
Mr. Keith Rosenbloom
Dr. and Mrs. Ronald M. Roth
Mr. and Mrs. Jack Rudin
Mr. Kevin M. Ryan
Mr. and Mrs. Mortimer Sackler
SAGE Labs
Mr. Francois St. Phalle
Mr. and Mrs. Alexander Saint-Amand
Mr. and Mrs. Sal Salibello
Mr. and Mrs. Nathan Sandler
Sanofi-Aventis Pharmaceuticals
Mr. Cesare F. Santangelo
Mr. James Sauer
Mr. and Mrs. George Saunders
Mr. Roger Savell
Mr. Peter M. Scheer
The Schiff Foundation
Seahorse Bioscience
William and Jacqueline Shaw Family Foundation
Ms. Marsha Shiff
Mr. Gil Shiva
Mr. and Mrs. Charles Shoemate
Mr. and Mrs. Mitchell Silverman
Mr. Daniel Skovronsky
Mr. Thomas Slater
Mr. and Mrs. Joshua Slocum
Mr. and Mrs. Albert H. Small
Ms. Tina B. Small
Mr. and Mrs. Joseph E. Smith
Solis Betancourt, Inc.
Mr. and Mrs. Richard Solomon
Mr. and Mrs. Gavin Solotar
Mr. and Mrs. Denis Somar
Mr. Maurice Sonnenberg
Mr. William Squier
Ms. Janice B. Stanton
Mrs. Edward D. Stone
Mr. and Mrs. Tom Strauss
Mr. Marc Sulam
Mr. Timothy Sullivan
Mr. Stephen Surgit
Mr. and Mrs. Alfred Taubman
Ms. Roxanne Taylor
Mr. Peter Thompson
Ms. Amy G. Treitel
Ms. Alexandra Trower and Mr. Jon Lindsey
Ms. Shanee Uberman
United Eway
Ms. Eunice Valdivia
Mr. Cyrus R. Vance
Verdura Inc.
Ms. Giselle F. Wagner and Mr. Paul A. Myerson
Mr. and Mrs. Sadek Wahba
Mr. and Mrs. Ross P. Waller
Mr. and Mrs. David Webber
Mr. Robert J. Weber, Jr.
Ms. Linda Weinstein
Mr. and Mrs. Ronald Weintraub
Mr. Arthur C. Weisenseel
Mr. Jeffrey A. Weiss
Mr. and Mrs. Pat Welsh
Mr. Clifford Whitehall
Mr. W. Grant Williams
Zenobia Therapeutics
Mr. Richard W. Ziegelausch
Mr. and Mrs. Eric Zinterhofer
Mr. Salvatore Zizza
Mr. Mortimer B. Zuckerman
Mr. and Mrs. Shelton Zuckerman

Gifts In Kind
Aeromexico
Amaryllis Flowers
Bedford Post Inn
Bottega Veneta
Café Milano
Ms. Gisette Capriati
Lila Castellaneta
CHDI Foundation
CooperKatz & Company
David Burke
Ms. Alexandra Villard de Borchgrave
Debevoise & Plimpton LLP
Delta Airlines
Derek Lam
Donna Karan International
Eckert Seamans Cherin Mellott, LLC
The Estée Lauder Companies Inc.
In Honor or Memory of:
Bea Abato
Elizabeth Alster
Marilyn Aneser
Antoinette Anti
Susan Battie
Joel Bieber
Jacques Boulanger
Albino Braiuca
Lily Brant
Anthony Corrao
Lincoln Crichlow
Marjorie Davis
Jack Edgar Detwiler
Pat Dixon
Kathleen Edwards
Hannah Elkin’s grandfather
Shirley Flaciu
Milton Forman
Dorothy Franklin
Sidney and Lillian Friedman
Irene Friedman
Rosemary Furman
Estelle Gelman
Lillian Z. Goda
John Green
Phyllis Hansen
Roy Harley
Jeanette Lee Hornstein
Rita Johnson
Dorthy Kaehler
Peggy Kelly
Horace E. Kelsey
Irina Kuhn
George Lang
Le Relais de Venise L’Entrecote
The Lebenthal Family
Mr. and Mrs. Marc Lefkowitz
Light of Healing Hope Foundation
Loews Miami Beach Hotel
Marc Jacobs
Martek Corporation
Martha Stewart Living Omnimedia
Mr. and Mrs. Emilio Matt
Meredith Viera and Valley Crest Productions
Metrokane
Microsoft Corporation
Moët and Chandon
Montblanc North America, LLC
Nancy Corzine
The Oak Room
Oscar Heyman
Pirelli Tire North America
Prestige Beverage Group
Quest Magazine
The Ritz-Carlton Destination Club
The Ritz-Carlton, South Beach
The Ritz-Carlton, Washington, DC
The Ritz-Carlton, Westchester
Riverside Theatre
Roundabout Theatre Company
Ms. Sharon T. Sager
Saks Fifth Avenue
Salvatore Ferragamo
Scalamandre
Shangsu Imperial Shih Tzu
Siegel+Gale
Sotheby’s
Mr. Joe Tomcho
UBS Private Wealth
Van Cleef & Arpels
Verdura
Weil Gotshal & Manges LLP
Mr. and Mrs. Buzz Zaino

We are grateful to all who contributed to the ADDF in 2011. For a complete list of donors, visit www.ALZDiscovery.org

EuroMotorcars Bethesda
Fast Forward, LLC.
Four Seasons Hotels and Resorts
Four Seasons Hotels, Washington, DC
Godiva Chocolatier
Mr. and Mrs. Mel Goodes
Graff Diamonds
Grey Goose
Imtech
The James Beard Foundation
Jennifer Miller Jewelry
Jenny Ng Designs
JetBlue Airways
Johnny Brookheart Jewelers
Judith Leiber
Judith Ripka Company
Jumeirah Essex House
Las Villas Hotel and Spa at Estrella del Mar
Mr. Leonard A. Lauder

Left to right: Jacqueline Beymer Lebenthal, Rosemary Furman, Rita Johnson, Estelle Gelman, Marilyn Aneser, Jacques Boulanger.
ADDf 2011 Grants

Preclinical Program – Academic

Tiziana Borsello, PhD
Istituto Di Ricerche Farmacologiche “Mario Negri”
Milano, Italy
*JNK specific inhibitor peptides: a novel strategy to prevent AD synaptopathy*
A W A R D : $100,000

Mauro Costa-Mattioli, PhD
Baylor College of Medicine
Houston, Texas
*A New Treatment for Cognitive Disorders*
A W A R D : $150,000

Chad Dickey, PhD
University of South Florida
Tampa, Florida
*A Novel Enantiomeric Diarylheptanoid Derived from Myrica cerifera as an Anti-Tau Therapeutic*
A W A R D : $150,000

Els Fieremans, PhD
New York University
New York, New York
*Axonal Density as a Non-Invasive Biomarker for the Early Prediction and Monitoring of Alzheimer’s Disease: an MRI Pilot Study*
A W A R D : $61,100

Lawrence Honig, MD, PhD
Taub Institute - Columbia University
New York, New York
*Magnetic Resonance Spectroscopy (MRS) to assess progression of Alzheimer’s Disease (AD)*
A W A R D : $125,000
**Jacques Boulanger Award to Dr. Lawrence S. Honig, Columbia University

Li Huang, PhD
Duke University
Durham, North Carolina
*Proteasome Activator as Drug Candidates in Alzheimer’s Disease*
A W A R D : $130,000

Peter F. Kador, PhD
University of Nebraska Medical Center
Omaha, Nebraska
*Orally Active Bioavailable Metal Attenuating Compounds For Alzheimer’s Disease*
A W A R D : $150,000

Rakez Kayed, PhD
University of Texas Medical Branch
Galveston, Texas
*Tau oligomers for treatment of Alzheimer’s Disease*
A W A R D : $75,500

Tae-Wan Kim, PhD
Columbia University Medical Center
New York, New York
*Development of screening assays for tauopathy in stem-cell derived neurons*
A W A R D : $125,000
Jeff A. Kuret, PhD  
Ohio State University  
Columbus, Ohio  
*Imaging agents for diagnosis of tauopathic neurodegenerative diseases*  
**AWARD**: $125,000

Donald Lo, PhD  
Duke University Medical Center  
Durham, North Carolina  
*Optimization and Pre-Clinical Proof of Concept of a New Drug Lead Candidate Series for Alzheimer's Disease*  
**AWARD**: $150,000

Kun Ping Lu, MD, PhD  
Beth Israel Deaconess Medical Center  
Boston, Massachusetts  
*Development and Efficacy Evaluation of Novel Immunotherapy for Human Tauopathies*  
**AWARD**: $143,500

Maria Morabito, PhD  
University of Massachusetts Medical School  
North Worcester, Massachusetts  
*Inhibitors of Mdm2-dependent PSD-95 ubiquitination as therapeutics for Alzheimer’s disease*  
**AWARD**: $121,100

Scott Noggle, PhD  
The New York Stem Cell Foundation  
New York, New York  
*Alzheimer’s disease modeling with patient-specific stem cells*  
**AWARD**: $136,000

Sathyanarayanan Puthanveettil, PhD  
The Scripps Research Institute  
La Jolla, California  
*Small molecule screen for modulators of kinesin function in mammalian brain*  
**AWARD**: $100,000

Chris Schaffer, PhD  
Cornell University  
Ithaca, New York  
*Role of leukocyte adhesion in impaired cerebral blood flow in Alzheimer’s disease*  
**AWARD**: $100,000

Eric Schon, PhD  
Columbia University  
New York, New York  
*Mitochondria-associated membranes in the pathogenesis of Alzheimer's disease: a new target for drug discovery*  
**AWARD**: $100,000

**The Alzheimer’s Drug Discovery Foundation / Alzheimer’s Foundation of America Award to Accelerate Drug Discovery**

David Schubert, PhD  
The Salk Institute  
La Jolla, California  
*Two Novel Compounds for the Treatment of Alzheimer’s Disease*  
**AWARD**: $90,000

D. Martin Watterson, PhD  
Northwestern University  
Chicago, Illinois  
*De-risking a novel kinase-targeted lead compound for future AD drug development*  
**AWARD**: $135,000

Ying Wu, MD  
NorthShore University HealthSystem Research Institute  
Evanston, Illinois  
*High Resolution Quantitative Magnetization Transfer Imaging in Entorhinal Cortex*  
**AWARD**: $85,300

**Preclinical Program – Biotechnology**

Steven P. Braithwaite, PhD  
Signum Biosciences, Inc.  
Monmouth Junction, New Jersey  
*Phosphoprotein phosphatase 2A (PP2A): A novel therapeutic target for Alzheimer’s disease; For Clinical Development of SIG1012*  
**AWARD**: $100,000

Rick Jack, PhD  
Madera Bionics, Inc.  
San Diego, California  
*Optimizing drug-like compounds that increase ApoE release from human astrocytes to treat Alzheimer’s Disease*  
**AWARD**: $294,375

Yukari Perrella  
Yuma Therapeutics Corporation  
Brookline, Massachusetts  
*Hsp90 Inhibitors for Alzheimer’s Disease*  
**AWARD**: $249,810

Michela Stucchi, PhD  
Axxam SpA  
Milano, Italy  
*Small Molecule P2X7 Antagonists for AD Treatment*  
**AWARD**: $250,000

**ADDF/Belfer ApoE Therapeutics Innovation Program**

Guojun Bu, PhD  
Mayo Clinic  
Jacksonville, Florida  
*Targeting ApoE and ApoE Receptor Pathways for Alzheimer’s Disease Therapy*  
**AWARD**: $100,000

Robert Mahley, MD, PhD  
The J. David Gladstone Institutes  
San Francisco, California  
*Identification of Small Molecules That Can Prevent Mitochondrial Dysfunction Associated with the Generation of Apolipoprotein E Fragments in Neurons*  
**AWARD**: $125,000
Steven Paul, MD  
Weill Cornell Medical College  
New York, New York  
Gene delivery of apolipoprotein E2 as a treatment for Alzheimer’s disease.  
**AWARD:** $250,000

Thomas Wisniewski, MD  
NYU School of Medicine  
New York, New York  
Development of peptidomimetic ApoE/Aβ Binding Inhibitors as an Effective and Non-toxic Therapeutic Approach for AD  
**AWARD:** $100,000

**Program to Accelerate Clinical Trials (PACT)**  
Marek Brzezinski, MD, PhD  
University of California, San Francisco  
San Francisco, California  
Effects of Brain Beta-Amyloid on Postoperative Cognition  
**AWARD:** $300,000

Paul Edison, MD, MRCP, PhD, FRCP  
Imperial College London  
London, United Kingdom  
Effect of Novel GLP1 analogue, Liraglutide on microglial activation and cerebral glucose metabolism in mild Alzheimer’s disease.  
**AWARD:** $458,000

Allan Levey, MD, PhD  
Emory University School of Medicine  
Atlanta, Georgia  
A phase Ila, double-blind, placebo-controlled, biomarker study of atomoxetine in subjects with mild cognitive impairment  
**AWARD:** $280,000

**ADDF-Association for Frontotemporal Degeneration Partnership Program**  
Adam Boxer, MD, PhD  
University of California, San Francisco  
San Francisco, California  
Biomarker Optimization for Progranulin Trials  
**AWARD:** $75,000

Steve Perrin, PhD  
ALS Therapy Development Institute  
Cambridge, Massachusetts  
Preclinical TDP43 Mouse Model  
**AWARD:** $125,000

William Seeley, MD  
University of California, San Francisco  
San Francisco, California  
Dynamic disease-monitoring network biomarkers for tracking frontotemporal dementia  
**AWARD:** $100,000

Charlotte Teunissen, PhD  
VU University Medical Center  
MB, Amsterdam, Netherlands  
Identification of novel discriminatory CSF biomarkers for different FTD subtypes by proteomics  
**AWARD:** $125,000

**ADDF-Charles River Aging Partnership Program**  
John Csernansky, MD  
Northwestern University  
Chicago, Illinois  
CRF1 receptors as a novel target for slowing age-related neurodegeneration  
**AWARD:** $100,000

Jerri Rook, PhD  
Vanderbilt Center of Neuroscience Drug Discovery  
In Vivo Characterization of Novel mGlu5 PAMs in Aged Rats  
**AWARD:** $125,000

**Conference Grants**  
James W. Aiken, PhD  
Keystone Symposia on Molecular and Cellular Biology  
Silverthorne, Colorado  
ApoE, Alzheimer’s and Lipoprotein Biology  
**AWARD:** $2,500

Jeffrey L. Cummings, MD  
Cleveland Clinic Lou Ruvo Center for Brain Health  
Las Vegas, Nevada  
Clinical Trials in Frontotemporal Degeneration and Related Disorders  
**AWARD:** $2,500

Zaven Khachaturian, PhD  
Campaign to Prevent Alzheimer’s Disease by 2020 [PAD2020]  
Potomac, Maryland  
PAD2020 Workgroup on: Novel Conceptual Models of Dementia  
Award: $5,000

Charla Lambert, PhD  
Cold Spring Harbor Laboratory  
Cold Spring Harbor, New York  
Workshop on Cognitive Aging  
**AWARD:** $2,500
**Alzheimer’s Drug Discovery Foundation**

**Statements of Financial Position**

**Assets**

<table>
<thead>
<tr>
<th>Description</th>
<th>Unaudited 12/31/11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td></td>
</tr>
<tr>
<td>Operating</td>
<td>$4,482,152</td>
</tr>
<tr>
<td>Restricted</td>
<td>362,052</td>
</tr>
<tr>
<td>Total cash and cash equivalents</td>
<td>4,844,204</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>2,840,985</td>
</tr>
<tr>
<td>Other assets</td>
<td>46,956</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$7,732,145</strong></td>
</tr>
</tbody>
</table>

**Liabilities and Net Assets**

**Liabilities**

- Accounts payable and accrued liabilities: $79,377
- Grants payable: 4,509,233
- **Total liabilities**: 4,588,610

**Net assets**

- Unrestricted: 1,844,517
- Temporarily restricted: 1,299,018
- **Total net assets**: 3,143,535

**Total liabilities and net assets**: **$7,732,145**

**Statement of Activities**

**Change In Net Assets**

**Unaudited 12/31/11**

**Support and Revenues**

**Support**

- Contributions: $5,881,661
- Grants: 125,000
- In-kind contributions: 2,584,682
- Proceeds from special events, net of direct expenses: 1,775,365

**Revenues**

- Conference registration fees and other income: 240,733
- Interest income: 6,320

**Total support and revenues**: 10,613,761

**Expenses**

- Program services: 6,947,182
- Fund raising: 726,102
- Management and general: 625,308
- **Total expenses**: 8,298,592

**Change in net assets**: 2,315,169

**Net assets, beginning of year**: 828,366

**Net assets, end of period**: **$3,143,535**

*Audited financials available upon request*
2011 Board of Governors

Honorary Chairman
Sandra Day O’Connor

Co-Chairmen
Leonard A. Lauder
Ronald S. Lauder

President
Nancy Corzine

Robert A. Belfer
Bonnie Pfeifer Evans
Melvin R. Goode
Randal Sandler
Alice Shure
Peter J. Solomon
Sally Susman

Ex Officio
Howard Fillit, MD

2011 Board of Overseers

Co-Chairmen
Susan Roth Katzke
Randal Sandler

Carol S. Boulanger
Charles Cangro
Julie Eskay-Eagle
Allan M. Green, MD, PhD, JD
Alexandra Lebenthal
Michael Lefenfeld
Elise Gelman Lefkowitz
Philip Lovett
Emilio Matt
Phebe Farrow Port
Sharon T. Sager
Joan Sutton Straus
Alison Zaino
Linda Zambelli

2011 Staff

Howard Fillit, MD
Executive Director
Nancy Lynn
Executive Vice President
Diane Duong
Finance Manager
Ethan Hutchinson
Director, Finance and Administration
Rachel Lane, PhD
Scientific Program Manager
Adam Liebling
Senior Grants Manager
Filomena Machleder
Assistant Director, Institutional Partnerships
Dina Miller
Development Associate
Aspasia Moundros
Executive Assistant/Operations Coordinator
Vina Orden
Director, Major Gifts
Kate Polidori
Assistant Director, Special Events
Natalie Romatz
Development Assistant, Institutional Partnerships
Allison Sawczyn
Assistant Director, Development
Diana Shineman, PhD
Assistant Director, Scientific Affairs
Niyati Thakker
Grants Associate
Mollie Wein
Development Assistant, Special Events

As of December 31, 2011
The ADDF has granted more than $51 million to fund nearly 400 programs in 18 countries.